Posts

BMS expands AI footprint with Nvidia, aiming for most powerful AI factory in life sciences

on
Bristol Myers Squibb (BMS) is expanding its partnership with Nvidia to build what it describes as the most powerful AI factory in the life sciences industry. The project will deploy a new NVIDIA DGX SuperPOD powered by eight DGX Vera Rubin NVL72 systems, giving BMS one of the most advanced and energy‑efficient NVIDIA infrastructures in life sciences; Vera Rubin is estimated to deliver up to ten times greater performance per megawatt than its predecessor. The expanded AI infrastructure will support BMS’s proprietary foundation models and NVIDIA BioNeMo‑based workflows, enabling researchers across oncology, hematology, cardiovascular, immunology and neuroscience to compress discovery timelines and run more complex agentic workflows. BMS’s existing DGX SuperPOD went live in 2024 and has already been used in oncology research, for example by training large‑scale imaging models on clinical trial data; the new Vera Rubin cluster will be co‑located in a commercial data center and will b...

A rising tide scenario: Why other Big Pharmas could follow Lilly into psychedelics

on

Dimerix acquires kidney injury drug DMX-652 from Mission Therapeutics as Arpeggio appears to wind down acute kidney program

on

Sanofi's Sarclisa Goes Hands-Free: Will It Matter to Physicians?

on

Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador

on

Novo Nordisk and Alvotech Face Continued FDA Scrutiny at Plants Tied to Recent FDA Rejections

on

Takeda's zasocitinib proves top-notch for difficult-to-treat psoriasis in Phase 3 update

on

BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields

on

GSK axes key cough drug candidate after mixed Phase 3 data end blockbuster hopes

on

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

on

Biopharma Bites: Boehringer’s 2Q, Keytruda Expansion, and Wegovy’s Market Domination

on

Brain implants that restore touch pass decade-long safety test

on

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

on